PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
30 sept. 2015 09h30 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - September 30, 2015) - Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer...
PharmaCyte Biotech Has Only Scratched the Surface With Its Cell-in-a-Box(R) Technology
17 août 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - August 17, 2015) - PharmaCyte Biotech Inc. (OTCQB: PMCB) has made a name for itself with the company’s potentially game-changing pancreatic cancer treatment, and also as the...
PharmaCyte Biotech's Improved Technology Attracting World Class Oncologists
30 juil. 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - July 30, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is a small international biotechnology firm, but you wouldn't know it by the company it keeps. How does PharmaCyte keep...
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board
21 juil. 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 21, 2015) - In the world of pharmaceuticals, the approval of a new drug is largely a matter of its relative performance rather than an absolute performance. That is,...
PharmaCyte Biotech's Cancer Treatment Shows "Complete Tumor Remission" in Published Preclinical Study
03 juin 2015 09h30 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - June 03, 2015) - PharmaCyte Biotech’s (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box®, was the star of the show in a recently released corporate...
PharmaCyte Biotech Awaits Pivotal U.S. Study Results Expected to Lead to Human Clinical Trials
23 avr. 2015 09h20 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - April 23, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is not a big company by any means, but their lineup of treatments is certainly standing tall these days. The...
Nuvilex, Inc. Engaged in "Cutting Edge" Cannabis Preclinical Studies Using Model Compounds With Cell-in-a-Box
29 oct. 2014 08h45 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 29, 2014) - Nuvilex, Inc. (OTCQB: NVLX) isn't letting the upcoming mid-term elections or the views in Washington, D.C., on medical marijuana slow down its...
Nuvilex, Inc. Moves Closer to "Bio-Artificial Pancreas" Diabetes Treatment With License for Insulin-Producing Cells
21 oct. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 21, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box®
platform technology. It started...